Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

7.620 +0.150 (+2.01%)
Streaming Delayed Price Updated: 11:58 AM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,828
Open 7.470
Bid (Size) 7.620 (8)
Ask (Size) 7.630 (31)
Prev. Close 7.470
Today's Range 7.450 - 7.625
52wk Range 5.195 - 10.67
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy. 
Via Chartmill
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-13.1%
-13.1%
1 Month
-6.4%
-6.4%
3 Month
+0.4%
+0.4%
6 Month
-9.1%
-9.1%
1 Year
+35.3%
+35.3%

More News

Read More
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results
Via Stocktwits
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert
Via Benzinga
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
Via Chartmill
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Via Benzinga
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens
Via Stocktwits
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Uncovering Potential: Aurinia Pharmaceuticals's Earnings Preview
Via Benzinga
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Is AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) following the Minervini trend for explosive growth?
Via Chartmill
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Via Stocktwits
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Via Benzinga
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 7.620
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 07/08/25 11:58 AM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 978.38M
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 978M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.